Fennec: PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Tag

 PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK® from its FDA Approval on September 20, 2022 Until September 20, 2029 ~

~ Additionally, the Company Has Three FDA Orange Book Listings Providing U.S. Patent Protection for PEDMARK® Until 2039 ~

https://finance.yahoo.com/news/fennec-pharmaceuticals-announces-pedmark-sodium-110000922.html